An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 and Sevelamer Carbonate (Renvela) in Chinese CKD Patients With Hyperphosphataemia
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Registrational; Therapeutic Use
- Sponsors Vifor Fresenius Medical Care Renal Pharma
- 09 Sep 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 09 Sep 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2020.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.